EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

AL Amyloidosis: Current Treatment and Outcomes

Margaret Locke iD, Maria Nieto iD

Advances in Hematology · 2025-01 · 2025 (1)

DOI: 10.1155/ah/7280805 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Hematology, online erschienen am 03.03.2025. Verfasst von Margaret Locke und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer, Northwell Health Cancer Institute & Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, New York, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Light chain AL amyloidosis is a systemic disorder involving tissue deposition of amyloid fibrils. Often delayed in diagnosis due to nonspecific systemic symptoms, AL amyloidosis must be confirmed on tissue biopsy. Once diagnosis is made, patients can be risk stratified based on the degree of organ involvement and high‐risk cytogenetic features. Currently, the only FDA‐approved first‐line therapy for AL amyloidosis is a combination regimen of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (DaraCyborD) with a goal of achieving a very good partial response (VGPR) after 4‐6 cycles of treatment. Autologous stem cell transplant can be considered in selected cases, although there is no robust evidence of superiority over chemotherapy alone. In the relapsed/refractory setting, numerous promising therapies are still under investigation including venetoclax especially for patients with translocation t (11; 14) and chimeric antigen receptor T‐cell therapy (CART) targeting B‐cell maturation antigen (BCMA). Trial Registration: ClinicalTrials.gov identifier: NCT04270175, NCT05451771, NCT04847453, and NCT05199337

Autor:innen und Institutionen

  • Department of Cancer, Northwell Health Cancer Institute & Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, New York, USA.

ORCID-Profile: Margaret Locke, Maria Nieto

Zitieren

APA

Locke, M., & Nieto, M. (2025). AL Amyloidosis: Current Treatment and Outcomes. Advances in Hematology, 2025(1). https://doi.org/10.1155/ah/7280805

Vancouver

Locke M, Nieto M. AL Amyloidosis: Current Treatment and Outcomes. Advances in Hematology. 2025;2025(1). doi:10.1155/ah/7280805

BibTeX
@article{Locke2025,
  author = {Locke, Margaret and Nieto, Maria},
  title = {AL Amyloidosis: Current Treatment and Outcomes},
  journal = {Advances in Hematology},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/ah/7280805}
}
Kostenlos starten →